Kornimate/medical-research-clean huggingface dataset:
the efficacy of hand narrow-band ultraviolet b (nbuvb) versus excilite treatment in vitiligo after minigrafting on the dorsal hands

Conditions: Vitiligo

Summary: to assess over a 25-week period the efficacy of hand-foot narrow-band ultraviolet b light versus focal 308-nm light treatment in inducing the return of pigment in vitiligo after skin minigraft transplants to the backs of the hands in patients with light brown to black skin. subject will undergo treatment for 13 weeks.

prospective investigator-blinded study involving 13 adult male and female subjects with vitiligo on the backs of both hands. punch minigrafting will be performed on both hands taking skin from the thighs and/or buttocks. light treatments will be administered starting at week one after grafting. one hand will receive narrow-band ultraviolet b light and the other will receive focal 308-nm light treatments. light treatments will be administered 3 times per week for 12 weeks. a long term follow-up visit will be completed at week 25. the investigator will evaluate the subjects at week 4, 7, 13 and 25 in addition to screening and baseline evaluations/procedures.

Eligibility criteria:
inclusion criteria: * male and female subjects 18 years of age or older * skin type iii-vi * vitiligo on both dorsal hands * history of stable vitiligo ( no new lesions and no more than 10% enlargement of existing lesions) for six months with an absence of kebner phenomenon (new lesions appearing after trauma to the skin) * refractory to topical steroids and immunomodulators exclusion criteria: * pregnant and/or breast-feeding females * history of skin cancer * history of taking photosensitizing medications * history of recent phototherapy (light therapy) or topical medications within one month prior to enrollment * history of organ transplantation * history of failed vitiligo skin transplantation * history of segmental vitiligo * history of 12 or more continuous light treatments

Keywords: vitiligo light treatment for vitiligo excilite
a phase iii study on the safety, pharmacokinetics and efficacy of coagulation factor viia

Conditions: Hemophilia A With Inhibitors; Hemophilia B With Inhibitors

Summary: the purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of coagulation factor viia (recombinant) for the treatment of bleeding episodes in hemophilia a or b patients with inhibitors to factor viii or ix in 12 patients ( birth to \<6 years old), and 12 patients (≥6 years old to \<12 years old).

a phase iii study on the safety, pharmacokinetics, and efficacy of coagulation factor viia (recombinant) in congenital hemophilia a or b pediatric patients from birth to \<12 years old with inhibitors to factor viii or ix: persept 2

Eligibility criteria:
inclusion criteria: * be male with a diagnosis of congenital hemophilia a or b of any severity * have one of the following: * a positive inhibitor test bu ≥5, or * a bethesda unit (bu) \<5 but expected to have a high anamnestic response to fviii or fix, as demonstrated from the patient's medical history, precluding the use of factor viii or ix products to treat bleeding episodes, or * a bu \<5 but expected to be refractory to increased dosing of fviii or fix, as demonstrated from the patient's medical history, precluding the use of factor viii or ix products to treat bleeding episodes * be aged from birth to \<12 years old * have experienced at least 3 bleeding episodes of any severity in the past 6 months * parents or legal guardians must be capable of understanding and be willing to comply with the conditions of the protocol * parents or legal guardians must have read, understood, and provided written informed consent exclusion criteria: * have any coagulation disorder other than hemophilia a or b * be immunosuppressed (i.e., the patient may not be receiving systemic immunosuppressive medication; cluster of differentiation 4 (cd4) counts at screening must be \>200/µl) * have a known allergy or hypersensitivity to rabbits * have platelet count \<100,000/ml * have had a major surgical procedure (e.g. orthopedic, abdominal) within 1 month prior to first administration of study drug * have received an investigational drug within 30 days of first study drug administration, or be expected to receive such drug during participation in this study
rates of positive basal cell carcinomas (bccs) in re-excisions

Conditions: Basal Cell Carcinoma

Summary: basal cell carcinoma (bcc) is the most common malignant growth in the world. treatment is primarily surgical with the goal of excising the growth in its entirety. when pathology results show that this has not been achieved, a re-excision is routinely performed. this study examines retrospectively the percentage of re-excisions of bcc that actually proved to be positive (exhibited growth) among those re-excisions performed at rambam healthcare campus and zvulun community medical center during the years 2008-10.


Eligibility criteria:
inclusion criteria: all patients that underwent an incomplete bcc excision during the years 2008-2010. exclusion criteria: patients that underwent an incomplete bcc excision and were subsequently referred to undergo a mohs procedure.

Keywords: basal cell carcinoma
thumb basal joint (cmc i) arthritis - preoperative anxiety/depression, outcome instruments, carpal cinematics and cost-utility

Conditions: Arthritis; Thumb Osteoarthritis; Arthropathy; Quality of Life

Summary: a project aiming to promote evidence based practice when treating thumb basal joint (cmc i) arthritis. we will aim to: 1) provide the minimal clinical difference of two general outcome instruments, 2) evaluate the association between pre-operative anxiety and/or depression and outcomes following trapeziectomy, 3) evaluate the effect of trapziectomy on carpal cinematics, 4) determine the cost-utility-ratio of trapeziectomy


Eligibility criteria:
inclusion criteria: * eaton-glickel \>2 arhritis * symptom duration \>3 months * pain vas \>30mm * no significant comorbidities, asa i-ii * fluent in finnish language exclusion criteria: * eaton-glickel \<2 * duration of symptoms \<3 months * vas \<30mm * asa \>ii * inflammatory joint disease * systemic corticosteroid or immunomodulatory medication * upper limb symptoms not explained with cmc i artritis * heavy smoking (\> 20 cigarettes per day) * alcohol or drug abuse * neurological condition affecting upper limb function * other ipsilateral upper limb condition requiring surgery
a study to learn about the study medicine (cibinqo) in people with atopic dermatitis.

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (cibinqo) for the potential treatment of atopic dermatitis in people under japanese medical practice.


Eligibility criteria:
inclusion criteria: 1. participants receiving this product for treatment of ad. 2. participants start receiving this product (commercial product) for the first time and no earlier than the contract date of this study, or participants who continues to receive this drug after hospital transfer can be registered retrospectively. exclusion criteria: 1. participants previously enrolled in this study at the same site.

Keywords: jak inhibitor atopic dermatitis (ad) abrocitinib eczema
telephone care management to address sleep problems in young children with autism

Conditions: Autism Spectrum Disorders; Insomnia

Summary: the investigators will conduct a randomized controlled trial comparing a telephone based intervention (tcm) to usual care (uc). tcm will feature a registered nurse providing a series of phone calls to assist caregivers in learning and modifying behavioral strategies that may help young children with autism to sleep better. objective (activity monitors) and subjective (rating scales) data will be collected by an independent research assistant at the end of the project. the investigators hypothesize that tcm improves sleep duration and decreases sleep problems relative to a usual care control condition (uc).

please see brief summary.

Eligibility criteria:
inclusion criteria: 1. insomnia 2. autism spectrum disorder 3. regular telephone service for caregiver 4. stable dose of medication exclusion criteria: 1. signs of obstructive sleep apnea (e.g., turning blue or stop breathing at night, recurrent snoring) 2. receptive language skills under 18 months
the effect of postpartum debriefing on the psychological outcomes

Conditions: Well-Being, Psychological

Summary: this study was planned to determine the effect of re-signification of birth in the early postpartum period on postpartum fear of childbirth, postpartum depression and birth trauma.

this study was contucted between february 2024 and june 2025 in turkey , as a single-blind randomized controlled experimental study to determine the effect of reinterpretation of birth on postpartum fear of childbirth, postpartum depression and birth trauma.during data collection, participants were informed about the purpose of the study and those who volunteered to participate in the research were accepted into the study by signing an informed consent form.data; when the study was approved, it was planned to be collected face to face within the first 12-24 hours after birth and by telephone within 6-8 weeks after birth. consort directive was followed in the research planning.

Eligibility criteria:
inclusion criteria: women who volunteer to participate in the study, whose mother tongue is turkish, who are between the ages of 18-45, who are at least primary school graduates, who are 37-42 weeks pregnant, who are nulliparous, who have a healthy pregnancy, who do not have a psychological condition or psychiatric disorder, who are monitored and cared for in the first 24 hours after birth at the tarsus state hospital maternity department, who approve of the reinterpretation of birth application to be carried out by the researcher will be included in the sample. exclusion criteria: those who did not volunteer to participate in the study, those who gave birth before the 37th week of pregnancy, those who were multiparous, those who had abnormal medical conditions during pregnancy (placental disorder, preeclampsia, premature birth threat, etc.), those whose native language is not turkish, those who have visual, speech and hearing impairments, those who had an emergency cesarean section, those who stayed in the hospital for less than 12 hours after birth, those who received a psychiatric diagnosis during the postpartum period (except those diagnosed with postpartum depression and post-traumatic stress disorder related to birth), those who could not be reached by phone during the follow-up of the study, women who developed complications in the first 24 hours after birth and required intensive care, those whose babies required neonatal intensive care during the postpartum period, those who experienced another life event that traumatized the woman during the postpartum period (harassment, rape, earthquake, accident, loss of a loved one) etc.) those who want to withdraw from the study at any stage of the study will not be included in the sample.

Keywords: debriefing, trauma, fear, depression
an exploratory study of near-infrared light therapy for mild to moderate alzheimer's disease

Conditions: Alzheimer Disease

Summary: this is an exploratory clinical study to evaluate the efficacy and safety of near-infrared light therapeutics in the treatment of mild to moderate alzheimer's disease.

this experiment adopts a single-center, single-arm research design. all the patients who signed the informed consent were screened, and qualified subjects could only be enrolled to receive nir therapy. this study plans to enroll 40 patients, all of whom meet the enrollment conditions will receive nir therapy, and the treatment is arranged to be once a day, once a 30min nir therapy, 6 times a week. the treatment lasted for 96 weeks, and follow-up and assessment were performed at baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 84 weeks, 96 weeks. during the first week of treatment, caregivers will be trained in the use of the nir device, and after the training is complete, researchers will also provide remote guidance, making visits as needed. changes in the 96-week adas-cog score from baseline were used as the primary endpoint to verify the efficacy and safety of the nir device.

Eligibility criteria:
inclusion criteria: * 50 - 90 years old, no gender limitation; * meeting the national institute on aging and alzheimer's association (2011 nia-aa) is likely the core clinical diagnostic criteria for alzheimer's disease; * the mmse score is ≥ 12 and ≤ 26; * the subjects should have primary school education or above and be able to complete the cognitive ability measurement and other tests stipulated in the protocol; * if taking cognitive-improving medications, the dose must be stable for at least 12 weeks prior to enrollment (stable for at least 4 weeks with psychotropic medications); * participants themselves or their guardians voluntarily participate and sign the informed consent. exclusion criteria: * any cognitive impairment or dementia not caused by alzheimer's disease, or co-existing with a serious mental illness (schizophrenia, bipolar disorder, major depression, etc.); * currently taking anticoagulant drugs; * a history of seizures or hemorrhagic stroke within 12 months; * allergic to sunlight or visible light or high sensitivity to head and neck skin; * severe head trauma or implants (bone nails, bone plates, excision, etc.); * malignant tumors; * any other medical condition that is not stabilized and adequately controlled (such as serious heart, respiratory, gastrointestinal, or kidney disease), or that the investigator believes may affect patient safety or interfere with the evaluation of the test; * persons addicted to alcohol or drugs; * women who are pregnant, nursing or planning a pregnancy; * participated in other clinical studies within 1 month before participating in this trial; * other conditions deemed unsuitable for clinical trial participation by the investigator.
irrigating fluid and blood coagulation

Conditions: Blood Coagulation Disorder

Summary: irrigating fluid absorbed during the endoscopic surgery may alter whole blood coagulation. however, little is known about the dose-response relationships of hemodilution. the investigators have therefore performed the present study to measure the effect of a mixture of 2.7% sorbitol-0.54% mannitol solution on the coagulation pathway according to the hemodilution level using a rotational thromboelastometry (rotem®) tests.


Eligibility criteria:
inclusion criteria: * healthy volunteers * age: 20 to 65 years * body weight \> 50 kg * volunteers who provided informed consent exclusion criteria: * hematologic disease * anticoagulant medication
effect of the addition of ketamine to sevoflurane anesthesia in electroconvulsive therapy

Conditions: Depressive Disorder

Summary: the investigators evaluate the effects of a subanesthetic dose of ketamine, administered as an adjunct to sevoflurane, on duration of seizure activity, hemodynamic profile and recovery times during electroconvulsive therapy (ect) in patients with major depression.

patients will randomly allocate, to either a sevoflurane-ketamine (group sk), sevoflurane-saline (group ss) receiving group. mean arterial pressure (map) and heart rate (hr) will record prior to anesthetic induction (t1); following anesthetic induction (t2); and 0, 1, 3, and 10 min after the seizure has ended (t3, t4, t5, and t6, respectively). motor and eeg seizure durations will be recorded.

Eligibility criteria:
inclusion criteria: * major depressive patients exclusion criteria: * pregnancy * have a history of myocardial infarction in the previous six months * atrial fibrillation or flutter * heart block * unregulated hypertension * cerebrovascular diseases * a known drug allergy

Keywords: electroconvulsive therapy; sevoflurane; ketamine
online mother-baby yoga with preterm infants and their mothers

Conditions: Preterm Birth; Anxiety; Development, Infant

Summary: the purpose of this study is to examine the effects of internet-based mother-baby yoga on preterm infants and their mothers.

mother-infant pairs were enrolled in the study. interventions applied as group sessions (maximum of 5 mother-infant pairs) for 6 weeks, once a week. yoga sessions before-after evaluations were done for both mother and infant outcomes.

Eligibility criteria:
inclusion criteria: * the infants whose gestational age between 32 0/7-36 6/7 week and corrected age's older than 6 weeks and their mothers * caregivers who have at least one smartphone or/and laptop or/and ipad * mothers and their babies who accept to register to the study exclusion criteria: * the infants who have a severe pathological sign in cranial screening * the infants who had ivh * the infants who have congenital abnormalities * the infants who have a metabolic or genetic diagnosis * the infants who have hearing or visual impairment * the mothers who had chronic depression history and/or mental retardation * the mothers who have a neurological or orthopedic diagnosis to the contraindication of exercise * the mothers who are pregnant

Keywords: premature infants yoga motor performance covid-19
prep at a syringe services program

Conditions: Hiv; Substance Use Disorders

Summary: the purpose of this study is to see if providing participants with pre-exposure prophylaxis (prep) medicine right away at the idea exchange will help participants remain in hiv negative.


Eligibility criteria:
inclusion criteria: 1. over the age of 18 2. speak either english or spanish 3. ability to provide informed consent 4. currently enrolled in the syringe services program 5. have a negative hiv rapid test result 6. estimated creatinine clearance \> 30 ml/minute exclusion criteria: 1. do not meet the above criteria of inclusion 2. decline to participate 3. test positive for hiv via rapid test 4. are pregnant or plan on becoming pregnant 5. have symptoms acute hiv. 6. any other comorbidities that at the discretion of the investigator would prevent the participant from participating in the study.
role of left ventricular pacing site

Conditions: Heart Failure; Cardiomyopathy, Dilated; Coronary Disease

Summary: cardiac resynchronization therapy has been shown to be effective in reducing symptoms and mortality in heart failure patients. however, very few is known about the importance of the left ventricular pacing site. we study in a random order 11 different left ventricular pacing sites and compare their hemodynamics using pressure-volume catheters. the consequences on the surface ecg are also assessed.

background. cardiac resynchronization therapy has been shown to be effective in reducing symptoms and mortality in heart failure patients. however, very few is known about the importance of the left ventricular pacing site. design. single-blind, monocentric, randomized cross-over study comparing 11 left ventricular pacing sites in a random order. intervention. left ventricular ddd pacing on 11 ventricular sites, prior to the implantation. at each pacing site, a control hemodynamics will be obtained in aai pacing at the same pacing rate. at each pacing site, 2 av delays, a short and a long one, will be assessed. eligibility criteria. patients referred for cardiac resynchronization therapy for heart failure outcomes. hemodynamic measures using pressure-volume catheters.

Eligibility criteria:
inclusion criteria: * heart failure referred for cardiac resynchronization therapy * nyha class iii or iv * informed consent form signed exclusion criteria: * hypertension not controlled by treatment * coronary ischemia not controlled by treatment

Keywords: heart failure cardiomyopathy, dilated coronary disease cardiac pacing, artificial hemodynamics randomized controlled trials single-blind study
documentation of heart failure in a gulf registry

Conditions: Heart Failure

Summary: in the middle east and the gulf, the general population have high cardiovascular risks like diabetes, hypertension, smoking and obesity. the average age of a patient with an acute coronary syndrome (acs) event is relatively young compared to western populations. women are multiparous and the rates of consanguinity marriages are high in this region of the world. these risk factors and conditions result in heart failure. great deal of knowledge is missing regarding the influence of these risk factors on heart failure presentation, the causes and management of heart failure in ambulatory patients in this region of the world.


Eligibility criteria:
inclusion criteria: 1. is over the age of 21. 2. has been diagnosed with heart failure, regardless of cause. 3. is presenting to the outpatient clinic of an internist or cardiologist for follow up. 4. provides a written consent. exclusion criteria: 1. prior enrolment in this study. 2. refusal or inability to provide consent.
pneumonia vaccine in bone marrow transplant recipients: usefulness of donor vaccination

Conditions: Bone Marrow Transplant

Summary: streptococcus pneumoniae, also known as pneumococcus, is a common cause of pneumonia in transplant patients. there has been a vaccine available for this infection called pneumovax. recently, a new vaccine for this infection called prevnar has been developed which may be more effective. vaccinating the bone marrow donor before transplant may boost the recipient's immune response to the vaccine after transplant. this study is done to compare how vaccinating the donor with one of the vaccines will affect the recipient's immune system response to the vaccine.

this is a randomized controlled trial designed to assess the immunogenicity of the new pneumococcal conjugate vaccine in a cohort of allogeneic hematopoietic stem cell transplant (allo-hsct) recipients. this will be done by using an approach of pre-transplant donor immunization with post-transplant recipient immunization. response will be compared with the standard 23-valent polysaccharide vaccine. it is hypothesized that the conjugate vaccine will provide an enhanced response in this group of immunosuppressed individuals who respond poorly to standard polysaccharide vaccines. specific objectives of this study are: * to determine the antibody response to both vaccines via a measurement of total antibody response and by the opsonophagocytic assay. this assay has the advantage of assessing if patient antibody responses represent truly functional antibodies that display opsonic activity against pneumococcus and is likely better correlated with protective efficacy. * to determine any acute adverse reactions of the conjugate vaccine in this population. results of this trial will help lay the foundation for the development of a rationale and optimal pneumococcal vaccination strategy that would prevent significant morbidity in this patient population. we hypothesize that pneumococcal conjugate vaccine, due to its t-cell dependent response will have greater immunogenicity and protective effect in an allo-hsct population by using a donor immunization strategy.

Eligibility criteria:
inclusion criteria: recipient - adult male or female marrow recipients who fulfill the following criteria will be eligible for the study: a) will undergo allogeneic-hsct in 2-3 weeks. b) no splenectomy c) not currently receiving ivig d) able to provide written informed consent and comply with study protocol e) age \> 16 donor - adult male or female marrow donors who fulfill the following criteria will be eligible for the study: 1. recipient of donor marrow agrees to participate in study. 2. no prior pneumococcal vaccination within the last 5 years 3. not on immunosuppressive medication (eg., corticosteroids) 4. no history of immunosuppressive condition that may potentially impair vaccine response eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis 5. no splenectomy 6. able to provide written informed consent and comply with study protocol 7. age \> 16

Keywords: bone marrow transplant pneumonia vaccine conjugate vaccine polysaccharide vaccine